At first blush the CGI-I results seem almost identical to Trofinetide's (NNZ-2566) P2 trial results, quick assessment suggests Trof may have the edge but not by much (3.5 vs. 3.6). Side effects also 'mild to moderate' in both drugs. Yes, GI issues more common in Trof as above, but headache, fatigue and dizziness more common in NA-921 (not mentioned above).
Path to market for NA-921 could also take longer than Trof given it would no longer get an Orphan Designation I believe?
And of course, let's not forget the 'jewel in the crown' NNZ-2591 has no comparative data in a P2 trial of Retts...
Happy to be corrected on any of the above.
Thanks for posting Kens.
NEU Price at posting:
$12.28 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)